Alcentra Capital (NASDAQ:ABDC) – Equities research analysts at Zacks Investment Research dropped their FY2018 earnings per share (EPS) estimates for shares of Alcentra Capital in a research report issued on Tuesday, May 8th, Zacks Investment Research reports. Zacks Investment Research analyst L. Thompson now forecasts that the asset manager will post earnings per share of $0.95 for the year, down from their prior estimate of $1.10. Zacks Investment Research also issued estimates for Alcentra Capital’s FY2019 earnings at $0.91 EPS.
Other research analysts have also issued research reports about the company. ValuEngine lowered Alcentra Capital from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 2nd. Keefe, Bruyette & Woods set a $7.00 target price on Alcentra Capital and gave the stock a “hold” rating in a report on Thursday, March 15th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $12.00.
Alcentra Capital (NASDAQ:ABDC) last posted its quarterly earnings results on Monday, May 7th. The asset manager reported $0.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.26 by $0.01. The firm had revenue of $8.18 million for the quarter, compared to analyst estimates of $8.23 million. Alcentra Capital had a positive return on equity of 10.44% and a negative net margin of 51.32%.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pacific Ridge Capital Partners LLC boosted its stake in Alcentra Capital by 221.8% in the 1st quarter. Pacific Ridge Capital Partners LLC now owns 449,260 shares of the asset manager’s stock valued at $3,127,000 after purchasing an additional 309,660 shares during the period. Stilwell Value LLC boosted its stake in Alcentra Capital by 20.7% in the 1st quarter. Stilwell Value LLC now owns 1,251,324 shares of the asset manager’s stock valued at $8,709,000 after purchasing an additional 214,277 shares during the period. Salzhauer Michael boosted its stake in Alcentra Capital by 160.3% in the 1st quarter. Salzhauer Michael now owns 123,121 shares of the asset manager’s stock valued at $857,000 after purchasing an additional 75,829 shares during the period. Bramshill Investments LLC bought a new stake in Alcentra Capital in the 4th quarter valued at $512,000. Finally, Caxton Corp bought a new stake in Alcentra Capital in the 4th quarter valued at $500,000. Institutional investors and hedge funds own 36.30% of the company’s stock.
In other Alcentra Capital news, Director Edward Grebow bought 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 10th. The shares were acquired at an average cost of $6.47 per share, with a total value of $32,350.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Branko Krmpotic bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 20th. The shares were acquired at an average cost of $6.15 per share, for a total transaction of $61,500.00. Following the completion of the acquisition, the insider now directly owns 14,000 shares in the company, valued at approximately $86,100. The disclosure for this purchase can be found here. Insiders have purchased a total of 19,750 shares of company stock worth $124,138 over the last three months. 4.96% of the stock is owned by insiders.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 5th. Investors of record on Friday, June 29th will be issued a dividend of $0.18 per share. This represents a $0.72 dividend on an annualized basis and a dividend yield of 10.76%. The ex-dividend date is Thursday, June 28th. Alcentra Capital’s payout ratio is presently 54.55%.
About Alcentra Capital
Alcentra Capital Corporation is a specialty finance company that operates as a non-diversified, closed-end management investment company. The Company operates as a business development company and a regulated investment company. It provides customized debt and equity financing solutions to lower middle-market companies, which are companies having annual earnings, before interest, taxes, depreciation and amortization of between $5 million and $15 million, and/or revenues of between $10 million and $100 million.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alcentra Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcentra Capital and related companies with MarketBeat.com's FREE daily email newsletter.